146 related articles for article (PubMed ID: 30660438)
1. [Incorporation of direct-acting oral anticoagulants to available therapeutic arsenal: Progress adequately?].
Caballero Requejo C; Urbieta Sanz E; Iniesta Navalón C; Gascón Cánovas JJ
Aten Primaria; 2019 Mar; 51(3):184-185. PubMed ID: 30660438
[No Abstract] [Full Text] [Related]
2. Anticoagulation in Older Adults.
Roth AR; Lazris A; Haskell H; James J
Am Fam Physician; 2020 Jun; 101(12):748-750. PubMed ID: 32538593
[No Abstract] [Full Text] [Related]
3. Direct oral anticoagulants (DOACs).
Vazquez S; Rondina MT
Vasc Med; 2015 Dec; 20(6):575-7. PubMed ID: 26285587
[TBL] [Abstract][Full Text] [Related]
4. Direct Oral to Parenteral Anticoagulants: Strategies for Inpatient Transition.
Lopez CN; Succar L; Varnado S; Donahue KR
J Clin Pharmacol; 2021 Jan; 61(1):32-40. PubMed ID: 32639606
[TBL] [Abstract][Full Text] [Related]
5. A Direct Oral Anticoagulant as a Cost Effective Alternative to Warfarin for Treatment of Provoked Venous Thrombosis.
Courtney W; Groarke E; Conway J; Conway E; Bourke D; Saunders J; Watts M; O'Keefe D
Ir Med J; 2016 Oct; 109(9):466. PubMed ID: 28125180
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Anticoagulants for Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Pilot Study.
Chapin TW; Leedahl DD; Brown AB; Pasek AM; Sand MG; Loy ML; Dyke CM
J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):523-530. PubMed ID: 32476465
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults.
Hasan SS; Kow CS; Curley LE; Baines DL; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):371-377. PubMed ID: 29741099
[TBL] [Abstract][Full Text] [Related]
8. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
[TBL] [Abstract][Full Text] [Related]
9. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
[TBL] [Abstract][Full Text] [Related]
10. Use of direct oral anticoagulants for postoperative venous thromboembolism prophylaxis after surgery for gynecologic malignancies.
Boo M; Sykes P; Simcock B
Int J Gynecol Cancer; 2022 Feb; 32(2):189-194. PubMed ID: 34992129
[TBL] [Abstract][Full Text] [Related]
11. Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants.
Tobu M; Iqbal O; Hoppensteadt D; Neville B; Messmore HL; Fareed J
Clin Appl Thromb Hemost; 2004 Oct; 10(4):301-9. PubMed ID: 15497016
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA.
Deitelzweig SB; Lovelace B; Christoph M; Lingohr-Smith M; Lin J; Fermann GJ
Adv Ther; 2020 Sep; 37(9):3942-3953. PubMed ID: 32699994
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients.
Walter E; Voit M; Eichhober G
Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):265-275. PubMed ID: 32700584
[TBL] [Abstract][Full Text] [Related]
15. Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis.
Casula M; Fortuni F; Fabris F; Leonardi S; Gnecchi M; Sanzo A; Greco A; Rordorf R
J Cardiovasc Med (Hagerstown); 2020 Aug; 21(8):570-576. PubMed ID: 32628422
[TBL] [Abstract][Full Text] [Related]
16. Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.
Yang M; Li J; Sun R; Wang Y; Xu H; Yang B; Wu X; Yu L
J Cancer Res Ther; 2019; 15(7):1541-1546. PubMed ID: 31939435
[TBL] [Abstract][Full Text] [Related]
17. Factors That Affect Time to Switch From Warfarin to a Direct Oral Anticoagulant After Change in the Reimbursement Criteria in Patients With Atrial Fibrillation.
Park S; Je NK
J Cardiovasc Pharmacol Ther; 2020 Jan; 25(1):57-64. PubMed ID: 31405298
[TBL] [Abstract][Full Text] [Related]
18. Dosing Recommendations for New Oral Anticoagulants.
Kreuzer J; Dugi K
JAMA; 2015 Jun 23-30; 313(24):2496. PubMed ID: 26103039
[No Abstract] [Full Text] [Related]
19. Dosing Recommendations for New Oral Anticoagulants--Reply.
Powell JR
JAMA; 2015 Jun 23-30; 313(24):2496-7. PubMed ID: 26103040
[No Abstract] [Full Text] [Related]
20. Factors Associated With the Choice of Oral Anticoagulant Class in the Older Patients: An Observational Study.
Pagès A; Sabatier R; Sallerin B
J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):332-337. PubMed ID: 32266832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
